Elahere is indicated as a treatment for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. These patients should havereceived one to three prior systemic treatment regimens.

The selection of patients for this therapy should be based on an FDA-approved test. Accelerated approval for this indication is based on tumor response rate and durability ofresponse. Continued approval may be contingent upon verification and description of clinicalbenefit in a confirmatory trial.